117 S1397 IS: Tribal Health Data Improvement Act of 2021
U.S. Senate
2021-04-27
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

II117th CONGRESS1st SessionS. 1397IN THE SENATE OF THE UNITED STATESApril 27, 2021Ms. Smith (for herself, Ms. Murkowski, Mr. Tester, Mr. Daines, Ms. Warren, and Mr. Cramer) introduced the following bill; which was read twice and referred to the Committee on Indian AffairsA BILLTo amend the Public Health Service Act with respect to the collection and availability of health data with respect to Indian Tribes and Tribal organizations, and for other purposes.1.Short titleThis Act may be cited as the Tribal Health Data Improvement Act of 2021.2.Collection and availability of health data with respect to Indian Tribes(a)Data collectionSection 3101(a)(1) of the Public Health Service Act (42 U.S.C. 300kk(a)(1)) is amended—(1)by striking , by not later than 2 years after the date of enactment of this title,; and(2)in subparagraph (B), by inserting Tribal, after State,.(b)Data reporting and disseminationSection 3101(c) of the Public Health Service Act (42 U.S.C. 300kk(c)) is amended—(1)by amending subparagraph (F) of paragraph (1) to read as follows:(F)the Indian Health Service, Indian Tribes, Tribal organizations, and epidemiology centers;; and(2)in paragraph (3), by inserting Indian Tribes, Tribal organizations, epidemiology centers, after Federal agencies,.(c)Protection and sharing of dataSection 3101(e) of the Public Health Service Act (42 U.S.C. 300kk(e)) is amended—(1)in paragraph (2)—(A)by striking .. and inserting .;(B)by striking The Secretary shall and inserting the following:(A)In generalThe Secretary shall; and(C)by adding at the end the following:(B)Epidemiology centers and Indian TribesWith respect to data access for epidemiology centers and Indian Tribes, the Secretary shall establish a data sharing strategy, in consultation with the Secretary’s Tribal Advisory Committee, for purposes of providing access to data to the epidemiology centers and Indian Tribes that protect data privacy and security and data governance while ensuring that epidemiology centers and Indian Tribes have access to data sources necessary to accomplish their public health responsibilities and plans for use.; and(2)by adding at the end the following new paragraph:(3)Tribal public health authorityBeginning not later than 180 days after the date of the enactment of the Tribal Health Data Improvement Act of 2021, the Secretary shall make available all requested data collected pursuant to this title with respect to health care and public health surveillance programs and activities, including such programs and activities that are federally supported or conducted, to—(A)the Indian Health Service;(B)Indian Tribes and Tribal organizations; and(C)epidemiology centers..(d)Technical updatesSection 3101 of the Public Health Service Act (42 U.S.C. 300kk) is amended—(1)by striking subsections (g) and (h); and(2)by redesignating subsection (i) as subsection (h).(e)DefinitionsAfter executing the amendments made by subsection (d), section 3101 of the Public Health Service Act (42 U.S.C. 300kk) is amended by inserting after subsection (f) the following new subsection:(g)DefinitionsIn this section:(1)The term epidemiology center means an epidemiology center established under section 214 of the Indian Health Care Improvement Act, including any epidemiology center serving Indian Tribes regionally or serving urban Indian organizations nationally that is receiving funding from the Indian Health Service.(2)The terms Indian Tribe and Tribal organization have the meanings given to the terms Indian tribe and tribal organization, respectively, in section 4 of the Indian Self-Determination and Education Assistance Act..(f)Technical correctionSection 3101(b) of the Public Health Service Act (42 U.S.C. 300kk(b)) is amended by striking Data analysis.— and all that follows through For each federally and inserting Data analysis.—For each federally.3.Improving health statistics reporting with respect to Indian Tribes(a)Technical aid to States and localitiesSection 306(d) of the Public Health Service Act (42 U.S.C. 242k(d)) is amended by inserting , Indian Tribes, Tribal organizations, and epidemiology centers after jurisdictions.(b)Cooperative health statistics systemSection 306(e)(3) of the Public Health Service Act (42 U.S.C. 242k(e)(3)) is amended by inserting , Indian Tribes, Tribal organizations, and epidemiology centers after health agencies.(c)Federal-State-Tribal cooperationSection 306(f) of the Public Health Service Act (42 U.S.C. 242k(f)) is amended—(1)by inserting , the Indian Health Service, after Commerce and Labor;(2)by inserting , Indian Tribes, Tribal organizations, and epidemiology centers after State and local health departments and agencies; and(3)by striking he shall and inserting the Secretary shall.(d)Registration area recordsSection 306(h)(1) of the Public Health Service Act (42 U.S.C. 242k(h)(1)) is amended—(1)by striking in his discretion and inserting in the discretion of the Secretary; and(2)by striking Hispanics, Asian Americans, and Pacific Islanders and inserting American Indians and Alaska Natives, Hispanics, Asians, and Native Hawaiian and other Pacific Islanders.(e)National Committee on Vital and Health StatisticsSection 306(k) of the Public Health Service Act (42 U.S.C. 242k(k)) is amended—(1)in paragraph (3), by striking , not later than 60 days after the date of the enactment of the Health Insurance Portability and Accountability Act of 1996, each place it appears; and(2)in paragraph (7), by striking Not later than 1 year after the date of the enactment of the Health Insurance Portability and Accountability Act of 1996, and annually thereafter, the Committee shall and inserting The Committee shall, on a biennial basis,.(f)Grants for assembly and analysis of data on ethnic and racial populationsSection 306(m)(4) of the Public Health Service Act (42 U.S.C. 242k(m)(4)) is amended—(1)in subparagraph (A)—(A)by striking Subject to subparagraph (B), the and inserting The; and(B)by striking and major Hispanic subpopulation groups and American Indians and inserting , major Hispanic subgroups, and American Indians and Alaska Natives; and(2)by amending subparagraph (B) to read as follows:(B)In carrying out subparagraph (A), with respect to American Indians and Alaska Natives, the Secretary shall—(i)in consultation with Indian Tribes, Tribal organizations, the Tribal Technical Advisory Group of the Centers for Medicare & Medicaid Services maintained under section 5006(e) of the American Recovery and Reinvestment Act of 2009, and the Tribal Advisory Committee established by the Centers for Disease Control and Prevention, and in coordination with epidemiology centers, develop guidance for State and local health agencies to improve the quality and accuracy of data with respect to the birth and death records of American Indians and Alaska Natives;(ii)confer with urban Indian organizations to develop guidance for State and local health agencies to improve the quality and accuracy of data with respect to the birth and death records of American Indians and Alaska Natives;(iii)enter into cooperative agreements with Indian Tribes, Tribal organizations, Urban Indian organizations, and epidemiology centers to analyze and address misclassification and undersampling of American Indians and Alaska Natives in data systems at the Federal, State, and local levels, with respect to—(I)birth and death records; and(II)Federal, State, and local health care and public health surveillance systems, including with respect to chronic and infectious diseases, unintentional injuries, environmental health, child and adolescent health, maternal health and mortality, foodborne and waterborne illness, reproductive health, and any other notifiable disease or condition;(iv)adopt, based on local, statewide, Tribal, and national best practices, uniform standards for the collection of health data on race and ethnicity;(v)encourage States to enter into data sharing agreements with Indian Tribes and epidemiology centers to improve the quality and accuracy of public health data regarding American Indians and Alaska natives, including by addressing misclassification and undersampling of American Indians and Alaska Natives in State and local public health data systems, including with respect to vital statistics, chronic and infectious diseases, unintentional injuries, environmental health, child and adolescent health, maternal health and mortality, foodborne and waterborne illness, reproductive health, and any other notifiable disease or condition;(vi)encourage States to adopt, based on local, statewide, Tribal, and national best practices, uniform standards for the collection of health data on race and ethnicity; and(vii)180 days after the date of enactment of the Tribal Health Data Improvement Act of 2021 and biennially thereafter, issue a report on—(I)which States have data sharing agreements with Indian Tribes, Tribal Organizations, urban Indian organizations, or epidemiology centers to improve the quality and accuracy of health data, listed by data system name; and(II)actions taken by the Director of the Centers for Disease Control and Prevention to encourage States to enter into data sharing agreements with Indian Tribes, Tribal Organizations, urban Indian organizations, and epidemiology centers to improve the quality and accuracy of health data..(g)DefinitionsSection 306 of the Public Health Service Act (42 U.S.C. 242k) is amended—(1)by redesignating subsection (n) as subsection (o); and(2)by inserting after subsection (m) the following:(n)In this section:(1)The term epidemiology center means an epidemiology center established under section 214 of the Indian Health Care Improvement Act, including any epidemiology center serving Indian Tribes regionally or serving urban Indian organizations nationally that is receiving funding from the Indian Health Service.(2)The terms Indian Tribe and Tribal organization have the meanings given to the terms Indian tribe and tribal organization, respectively, in section 4 of the Indian Self-Determination and Education Assistance Act.(3)The term Urban Indian organization has the meaning given to that term in section 4 of the Indian Health Care Improvement Act..(h)Authorization of appropriationsSection 306(o) of the Public Health Service Act, as redesignated by subsection (g), is amended to read as follows:(o)To carry out this section, there is authorized to be appropriated $185,000,000 for each of the fiscal years 2021 through 2025..


114 S2055 RS: Medical Countermeasure Innovation Act of 2015
U.S. Senate
2015-09-17
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IICalendar No. 388114th CONGRESS2d SessionS. 2055IN THE SENATE OF THE UNITED STATESSeptember 17, 2015Mr. Burr (for himself, Mr. Casey, Mr. Isakson, and Mr. Roberts) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsMarch 14, 2016Reported by Mr. Alexander, with an amendmentStrike out all after the enacting clause and insert the part printed in italicA BILLTo amend the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to
			 national health security.

 1.Short titleThis Act may be cited as the Medical Countermeasure Innovation Act of 2015.
		2.Medical countermeasure guidelines
 (a)Strategic national stockpile and security countermeasure procurementsSection 319F–2 of the Public Health Service Act (42 U.S.C. 247d–6b) is amended— (1)in subsection (a), by adding at the end the following:

 (3)Utilization guidelinesThe Secretary shall ensure timely and accurate recommended utilization guidelines for qualified countermeasures (as defined in section 319F–1), qualified pandemic and epidemic products (as defined in section 319F–3), and security countermeasures (as defined in subsection (c)), including for such products in the stockpile.; and
 (2)in subsection (g)— (A)by amending paragraph (4) to read as follows:

 (4)Report on security countermeasure procurementNot later than March 1 of each year in which the Secretary determines that the amount of funds available for procurement of security countermeasures is less than $1,500,000,000, the Secretary shall submit to the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives a report detailing the amount of such funds available for procurement and the impact such amount of funding will have—
 (A)in meeting the security countermeasure needs identified under this section; and (B)on the annual Public Health Emergency Medical Countermeasures Enterprise and Strategy Implementation Plan (pursuant to section 2811(d))..
					3.Clarification on BARDA contracting authority
 (a)In generalSection 319F–2(g) of the Public Health Service Act (42 U.S.C. 247d–6b(g)) is amended by adding at the end the following:

 (5)Clarification on contracting authorityThe Secretary, acting through the Director of the Biomedical Advanced Research and Development Authority, shall carry out the programs funded by the special reserve fund (for the procurement of security countermeasures under subsection (c) and for carrying out section 319L), including the execution of procurement contracts, grants, and cooperative agreements pursuant to this section and section 319L..
 (b)BARDA contracting authoritySection 319L(c)(3) of the Public Health Service Act (42 U.S.C. 247d–7c) is amended by inserting , including the execution of procurement contracts, grants, and cooperative agreements pursuant to this section before the period.
 4.Countermeasures budget planSection 2811(b)(7) of the Public Health Service Act (42 U.S.C. 300hh–10(b)(7)) is amended—
 (1)by striking the first sentence and inserting Develop, and update not later than March 1 of each year, a coordinated 5-year budget plan based on the medical countermeasure priorities described in subsection (d), including with respect to chemical, biological, radiological, and nuclear agent or agents that may present a threat to the Nation, including such agents that are novel or emerging infectious diseases, and the corresponding efforts to develop qualified countermeasures (as defined in section 319F–1), security countermeasures (as defined in section 319F–2), and qualified pandemic or epidemic products (as defined in section 319F–3) for each such threat.;
 (2)in subparagraph (C), by striking ; and and inserting a semicolon; (3)in subparagraph (D), by striking to the appropriate committees of Congress upon request. and inserting , not later than March 15 of each year, to the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives; and; and
 (4)by adding at the end the following:  (E)not later than March 15 of each year, be made publicly available..
 5.Prioritizing the animal rule guidanceSection 565(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4(c)) is amended by adding at the end the following:

 (3)Written explanationThe Secretary shall provide to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a written explanation, not later than the last day of each month after the date of enactment of the Medical Countermeasure Innovation Act of 2015 in which the Secretary fails to finalize such guidance, for why the Secretary has failed to finalize the guidance as required by this subsection..
 6.Streamlining the project bioshield procurement processSection 319F–2(c) of the Public Health Service Act (42 U.S.C. 247d–6b(c)) is amended— (1)in paragraph (4)(A)(ii), by striking make a recommendation under paragraph (6) that the special reserve fund as defined in subsection (h) be made available for the procurement of such countermeasure and inserting make available the special reserve fund as defined in subsection (h) for procurement of such countermeasure, as applicable;
 (2)in paragraph (6)— (A)by striking subparagraphs (A), (B), and (E);
 (B)by redesignating subparagraphs (C) and (D) as subparagraphs (A) and (B), respectively; (C)by amending subparagraph (A), as so redesignated, to read as follows:

 (A)Notice to appropriate congressional committeesThe Secretary shall notify the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives of each decision to make available the special reserve fund as defined in subsection (h) for procurement of a security countermeasure, including, where available, the number of, the nature of, and other information concerning potential suppliers of such countermeasure, and whether other potential suppliers of the same or similar countermeasures were considered and rejected for procurement under this section and the reasons therefore.; and
 (D)in the heading, by striking Recommendation for president's approval and inserting Recommendations for procurement; and (3)in paragraph (7)—
 (A)by striking subparagraph (A); (B)by striking subparagraph (B) and inserting the following:

 (A)Payments from special reserve fundThe special reserve fund as defined in subsection (h) shall be available for payments made by the Secretary to a vendor for procurement of a security countermeasure in accordance with the provisions of this paragraph.; and
 (C)by redesignating subparagraph (C) as subparagraph (B). 7.Priority review to encourage treatments for agents that present national security threatsSubchapter E of chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb et seq.) is amended by inserting after section 565 the following:

				565A.Priority review to encourage treatments for agents that present national security threats
 (a)DefinitionsIn this section: (1)The term priority review with respect to a human drug application as defined in section 735(1), means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures in the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Food and Drug Administration Safety and Innovation Act.
 (2)Priority review voucherThe term priority review voucher means a voucher issued by the Secretary to the sponsor of a material threat medical countermeasure application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 505(b)(1) or section 351 of the Public Health Service Act after the date of approval of the material threat medical countermeasure application.
 (3)Material threat medical countermeasure applicationThe term material threat medical countermeasure application means an application that— (A)is a human drug application as defined in section 735(1)—
 (i)to prevent, or treat harm from a biological, chemical, radiological, or nuclear agent identified as a material threat under section 319F–2(c)(2)(A)(ii) of the Public Health Service Act, or
 (ii)to mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, or biological product against such agent;
 (B)the Secretary deems eligible for priority review; (C)is approved after the date of enactment of the Medical Countermeasure Innovation Act of 2015; and
 (D)is for a human drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under section 505(b)(1) or section 351 of the Public Health Service Act.
							(b)Priority review voucher
 (1)In generalThe Secretary shall award a priority review voucher to the sponsor of a material threat medical countermeasure application upon approval by the Secretary of such material threat medical countermeasure application.
 (2)TransferabilityThe sponsor of a material threat medical countermeasure application that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher to a sponsor of a human drug for which an application under section 505(b)(1) or section 351 of the Public Health Service Act will be submitted after the date of the approval of the material threat medical countermeasure application. There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.
						(3)Notification
 (A)In generalThe sponsor of a human drug application shall notify the Secretary not later than 90 calendar days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section.
 (B)Transfer after noticeThe sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph (A) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.
							(c)Priority review user fee
 (1)In generalThe Secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the Secretary a fee determined under paragraph (2). Such fee shall be in addition to any fee required to be submitted by the sponsor under chapter VII.
 (2)Fee amountThe amount of the priority review user fee shall be determined each fiscal year by the Secretary and based on the average cost incurred by the agency in the review of a human drug application subject to priority review in the previous fiscal year.
 (3)Annual fee settingThe Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2015, for that fiscal year, the amount of the priority review user fee.
						(4)Payment
 (A)In generalThe priority review user fee required by this subsection shall be due upon the submission of a human drug application under section 505(b)(1) or section 351 of the Public Health Service Act for which the priority review voucher is used.
 (B)Complete applicationAn application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary's procedures for paying such fees.
 (C)No waivers, exemptions, reductions, or refundsThe Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section.
 (5)Offsetting collectionsFees collected pursuant to this subsection for any fiscal year— (A)shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and
 (B)shall not be collected for any fiscal year except to the extent provided in advance in appropriation Acts.
 (d)Notice of Issuance of Voucher and Approval of Products Under VoucherThe Secretary shall publish a notice in the Federal Register and on the Internet Website of the Food and Drug Administration not later than 30 calendar days after the occurrence of each of the following:
 (1)The Secretary issues a priority review voucher under this section. (2)The Secretary approves a drug pursuant to an application submitted under section 505(b) of this Act or section 351(a) of the Public Health Service Act for which the sponsor of the application used a priority review voucher under this section.
 (e)Eligibility for other programsNothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this Act, except that no sponsor of a material threat medical countermeasure application may receive more than one priority review voucher with respect to such drug.
 (f)Relation to other provisionsThe provisions of this section shall supplement, not supplant, any other provisions of this Act or the Public Health Service Act that encourage the development of medical countermeasures..

 1.Short titleThis Act may be cited as the Medical Countermeasure Innovation Act of 2016.
		2.Medical countermeasure guidelines
 (a)Strategic national stockpile and security countermeasure procurementsSection 319F–2 of the Public Health Service Act (42 U.S.C. 247d–6b) is amended— (1)in subsection (a), by adding at the end the following:

 (3)Utilization guidelinesThe Secretary shall ensure timely and accurate recommended utilization guidelines for qualified countermeasures (as defined in section 319F–1), qualified pandemic and epidemic products (as defined in section 319F–3), and security countermeasures (as defined in subsection (c)), including for such products in the stockpile.; and
 (2)in subsection (g)— (A)by amending paragraph (4) to read as follows:

 (4)Report on security countermeasure procurementNot later than March 1 of each year in which the Secretary determines that the amount of funds available for procurement of security countermeasures is less than $1,500,000,000, the Secretary shall submit to the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives a report detailing the amount of such funds available for procurement and the impact such amount of funding will have—
 (A)in meeting the security countermeasure needs identified under this section; and (B)on the annual Public Health Emergency Medical Countermeasures Enterprise and Strategy Implementation Plan (pursuant to section 2811(d)).; and
					3.Clarification on BARDA contracting authority
 (a)In generalSection 319F–2(g) of the Public Health Service Act (42 U.S.C. 247d–6b(g)) is amended by adding at the end the following:

 (5)Clarification on contracting authorityThe Secretary, acting through the Director of the Biomedical Advanced Research and Development Authority, shall carry out the programs funded by the special reserve fund (for the procurement of security countermeasures under subsection (c) and for carrying out section 319L), including the execution of procurement contracts, grants, and cooperative agreements pursuant to this section and section 319L..
 (b)BARDA contracting authoritySection 319L(c)(3) of the Public Health Service Act (42 U.S.C. 247d-7c) is amended by inserting , including the execution of procurement contracts, grants, and cooperative agreements pursuant to this section before the period.
 4.Countermeasures budget planSection 2811(b)(7) of the Public Health Service Act (42 U.S.C. 300hh–10(b)(7)) is amended—
 (1)by striking the first sentence and inserting Develop, and update not later than March 1 of each year, a coordinated 5-year budget plan based on the medical countermeasure priorities described in subsection (d), including with respect to chemical, biological, radiological, and nuclear agent or agents that may present a threat to the Nation, including such agents that are novel or emerging infectious diseases, and the corresponding efforts to develop qualified countermeasures (as defined in section 319F–1), security countermeasures (as defined in section 319F–2), and qualified pandemic or epidemic products (as defined in section 319F–3) for each such threat.;
 (2)in subparagraph (C), by striking ; and and inserting a semicolon; (3)in subparagraph (D), by striking to the appropriate committees of Congress upon request. and inserting , not later than March 15 of each year, to the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives; and; and
 (4)by adding at the end the following:  (E)not later than March 15 of each year, be made publicly available in a manner that does not compromise national security..
 5.Medical countermeasures innovationSection 319L(c)(4) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(4)) is amended by adding at the end the following:

				(E)Medical countermeasures innovation partner
 (i)In generalTo support the purposes described in paragraph (2), the Secretary, acting through the Director of BARDA, may enter into an agreement (including through the use of grants, contracts, cooperative agreements, or other transactions as described in paragraph (5)) with an independent, non-profit entity to—
 (I)foster and accelerate the development and innovation of medical countermeasures and technologies that may assist advanced research and development of qualified countermeasures and qualified pandemic or epidemic products, including through the use of strategic venture capital practices and methods;
 (II)promote the development of new and promising technologies that address urgent medical countermeasure needs, as identified by the Secretary;
 (III)address unmet public health needs that are directly related to medical countermeasure requirements, such as novel antimicrobials for multidrug resistant organisms and multiuse platform technologies for diagnostics, prophylaxis, vaccines, and therapeutics; and
 (IV)provide expert consultation and advice to foster viable medical countermeasure innovators, including helping qualified countermeasure innovators navigate unique industry challenges with respect to developing chemical, biological, radiological, and nuclear countermeasure products.
						(ii)Eligibility
 (I)In generalTo be eligible to enter into an agreement under clause (i) an entity shall—
 (aa)be an independent, non-profit entity; (bb)have a demonstrated record of being able to create linkages between innovators and investors and leverage such partnerships and resources for the purpose of addressing identified strategic needs of the Federal Government;
 (cc)have experience in promoting novel technology innovation;
 (dd)be problem driven and solution focused based on the needs, requirements, and problems identified by the Secretary under clause (iv);
 (ee)demonstrate the ability, or the potential ability, to promote the development of medical countermeasure products;
 (ff)demonstrate expertise, or the capacity to develop or acquire expertise, related to technical and regulatory considerations with respect to medical countermeasures; and
 (gg)not be within the Department of Health and Human Services. (II)Partnering experienceIn selecting an entity with which to enter into an agreement under clause (i), the Secretary shall place a high value on the demonstrated experience of the entity in partnering with the Federal Government to meet identified strategic needs.
 (iii)Not agencyAn entity that enters into an agreement under clause (i) shall not be deemed to be a Federal agency for any purpose, including for any purpose under title 5, United States Code.
 (iv)DirectionPursuant to an agreement entered into under this subparagraph, the Secretary, acting through the Director of BARDA, shall provide direction to the entity that enters into an agreement under clause (i). As part of this agreement the Director of BARDA shall—
 (I)communicate the medical countermeasure needs, requirements, and problems to be addressed by the entity under the agreement;
 (II)develop a description of work to be performed by the entity under the agreement;
 (III)provide technical feedback and appropriate oversight over work carried out by the entity under the agreement, including subsequent development and partnerships consistent with the needs and requirements set forth in this subparagraph;
 (IV)ensure fair consideration of products developed under the agreement in order to maintain competition to the maximum practical extent, as applicable and appropriate under applicable provisions of this section; and
 (V)ensure, as a condition of the agreement—
 (aa)a comprehensive set of policies that demonstrate a commitment to transparency and accountability;
 (bb)protection against conflicts of interest through a comprehensive set of policies that address potential conflicts of interest, ethics, disclosure, and reporting requirements;
 (cc)that the entity provides monthly accounting on the use of funds provided under such agreement; and
 (dd)that the entity provides on a quarterly basis, reports regarding the progress made toward meeting the identified needs set forth in the agreement.
 (v)Supplement not supplantActivities carried out under this subparagraph shall supplement, and not supplant, other activities carried out under this section.
 (vi)No establishment of entityTo prevent unnecessary duplication and target resources effectively, nothing in this subparagraph shall be construed to authorize the Secretary to establish within the Department of Health and Human Services an entity for the purposes of carrying out this subparagraph.
 (vii)Transparency and oversightUpon request, the Secretary shall provide to Congress the information provided to the Secretary under clause (iv)(V)(dd).
 (viii)Independent evaluationNot later than 4 years after the date of enactment of this subparagraph, the Government Accountability Office shall conduct an independent evaluation, and submit to the Secretary and the appropriate committees of Congress a report, concerning the activities conducted under this subparagraph. Such report shall include recommendations with respect to any agreement or activities carried out pursuant to this subparagraph.
 (ix)SunsetThis subparagraph shall have no force or effect after September 30, 2022..
 6.Streamlining the project bioshield procurement processSection 319F–2(c) of the Public Health Service Act (42 U.S.C. 247d–6b(c)) is amended— (1)in paragraph (4)(A)(ii), by striking make a recommendation under paragraph (6) that the special reserve fund as defined in subsection (h) be made available for the procurement of such countermeasure and inserting and subject to the availability of appropriations, make available the special reserve fund as defined in subsection (h) for procurement of such countermeasure, as applicable;
 (2)in paragraph (6)— (A)by striking subparagraphs (A), (B), and (E);
 (B)by redesignating subparagraphs (C) and (D) as subparagraphs (A) and (B), respectively; (C)by amending subparagraph (A), as so redesignated, to read as follows:

 (A)Notice to appropriate congressional committeesThe Secretary shall notify the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives of each decision to make available the special reserve fund as defined in subsection (h) for procurement of a security countermeasure, including, where available, the number of, the nature of, and other information concerning potential suppliers of such countermeasure, and whether other potential suppliers of the same or similar countermeasures were considered and rejected for procurement under this section and the reasons therefore.; and
 (D)in the heading, by striking Recommendation for president's approval and inserting Recommendations for procurement; and (3)in paragraph (7)—
 (A)by striking subparagraph (A); (B)by striking subparagraph (B) and inserting the following:

 (A)Payments from special reserve fundThe special reserve fund as defined in subsection (h) shall be available for payments made by the Secretary to a vendor for procurement of a security countermeasure in accordance with the provisions of this paragraph.; and
 (C)by redesignating subparagraph (C) as subparagraph (B). 7.Priority review to encourage treatments for agents that present national security threatsSubchapter E of chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb et seq.) is amended by inserting after section 565 the following:

				565A.Priority review to encourage treatments for agents that present national security threats
 (a)DefinitionsIn this section: (1)The term priority review with respect to a human drug application as defined in section 735(1), means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures in the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Food and Drug Administration Safety and Innovation Act.
 (2)Priority review voucherThe term priority review voucher means a voucher issued by the Secretary to the sponsor of a material threat medical countermeasure application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 505(b)(1) or section 351(a) of the Public Health Service Act after the date of approval of the material threat medical countermeasure application.
 (3)Material threat medical countermeasure applicationThe term material threat medical countermeasure application means an application that— (A)is a human drug application as defined in section 735(1)—
 (i)to prevent, or treat harm from a biological, chemical, radiological, or nuclear agent identified as a material threat under section 319F–2(c)(2)(A)(ii) of the Public Health Service Act, or
 (ii)to mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, or biological product against such agent; and
 (B)the Secretary deems eligible for priority review; (C)is approved after the date of enactment of the Medical Countermeasure Innovation Act of 2016; and
 (D)is for a human drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under section 505(b)(1) or section 351(a) of the Public Health Service Act.
							(b)Priority review voucher
 (1)In generalThe Secretary shall award a priority review voucher to the sponsor of a material threat medical countermeasure application upon approval by the Secretary of such material threat medical countermeasure application.
 (2)TransferabilityThe sponsor of a material threat medical countermeasure application that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher to a sponsor of a human drug for which an application under section 505(b)(1) or section 351(a) of the Public Health Service Act will be submitted after the date of the approval of the material threat medical countermeasure application. There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.
						(3)Notification
 (A)In generalThe sponsor of a human drug application shall notify the Secretary not later than 90 calendar days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section.
 (B)Transfer after noticeThe sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph (A) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.
							(c)Priority review user fee
 (1)In generalThe Secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the Secretary a fee determined under paragraph (2). Such fee shall be in addition to any fee required to be submitted by the sponsor under chapter VII.
 (2)Fee amountThe amount of the priority review user fee shall be determined each fiscal year by the Secretary and based on the average cost incurred by the agency in the review of a human drug application subject to priority review in the previous fiscal year.
 (3)Annual fee settingThe Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2015, for that fiscal year, the amount of the priority review user fee.
						(4)Payment
 (A)In generalThe priority review user fee required by this subsection shall be due upon the submission of a human drug application under section 505(b)(1) or section 351(a) of the Public Health Services Act for which the priority review voucher is used.
 (B)Complete applicationAn application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary's procedures for paying such fees.
 (C)No waivers, exemptions, reductions, or refundsThe Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section.
 (5)Offsetting collectionsFees collected pursuant to this subsection for any fiscal year— (A)shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and
 (6)shall not be collected for any fiscal year except to the extent provided in advance in appropriation Acts.
 (d)Notice of Issuance of Voucher and Approval of Products Under VoucherThe Secretary shall publish a notice in the Federal Register and on the Internet Website of the Food and Drug Administration not later than 30 calendar days after the occurrence of each of the following:
 (1)The Secretary issues a priority review voucher under this section. (2)The Secretary approves a drug pursuant to an application submitted under section 505(b) of this Act or section 351(a) of the Public Health Service Act for which the sponsor of the application used a priority review voucher under this section.
 (e)Eligibility for other programsNothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this Act, except that no sponsor of a material threat medical countermeasure application may receive more than one priority review voucher issued under any section of this Act with respect to such drug.
 (f)Relation to other provisionsThe provisions of this section shall supplement, not supplant, any other provisions of this Act or the Public Health Service Act that encourage the development of medical countermeasures..
		8.GAO report
 (a)StudyThe Comptroller General of the United States shall conduct a study on the effectiveness of priority review vouchers under section 565A of the Federal Food, Drug, and Cosmetic Act (as added by section 7) in providing incentives for the development of material threat medical countermeasures applications under such section 565A. In conducting such study, the Comptroller General shall examine the following:
 (1)The impact of the priority review voucher in attracting investment into the development of material threat medical countermeasures and the impact of such investment, as applicable, on the development of such countermeasures.
 (2)How the drugs for which priority review vouchers were awarded under such section 565A— (A)addressed identified medical countermeasure needs; and
 (B)impacted United States preparedness against chemical, biological, radiological, and nuclear threats, including both identified threats and naturally-occurring threats.
 (3)How many material threat medical countermeasures were licensed or approved, or otherwise significantly advanced in clinical development, in the 10 years following the enactment of such section 565A compared to the 10 years prior to the enactment of such section.
 (4)An analysis of the drugs for which such priority review vouchers were used, which shall include— (A)the indications for which such drugs were approved under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) or section 351(a) of the Public Health Service Act (42 U.S.C. 262);
 (B)whether unmet medical needs were addressed through the approval of such drugs, including, for each such drug—
 (i)if an alternative therapy was previously available to treat the indication; and (ii)if the drug provided a benefit or advantage over another available therapy;
 (C)the value of the priority review voucher if transferred; and (D)the length of time between the date on which a priority review voucher was awarded and the date on which it was used.
 (5)With respect to the priority review voucher program under such section 565A— (A)how many priority review vouchers were awarded under such section 565A and how many of such awarded vouchers were redeemed for priority review of a drug application in the 10 years following the date of enactment of such section;
 (B)the resources associated with the Food and Drug Administration implementation of such section 565A and review of applications for which a voucher awarded under such section 565A is redeemed for priority review; and
 (C)recommendations, if any, with respect to how such section 565A could be improved to better achieve the objective of incentivizing the timely development of medical countermeasures to address identified chemical, biological, radiological, and nuclear threats, including for medical countermeasures that might otherwise not be developed, potentially eligible for an emergency use authorization, licensed, or approved.
 (b)ConsultationsIn conducting the study under subsection (a), the Comptroller General of the United States shall consult with—
 (1)drug manufacturers involved in the research and development of medical countermeasures to address biological, chemical, radiological, and nuclear threats;
 (2)stakeholders involved in investing in the research and development of medical countermeasures, including venture capitalists;
 (3)the Federal Government agencies responsible for advancing, reviewing, and procuring medical countermeasures, including—
 (A)the Department of Health and Human Services, including the Office of the Assistant Secretary for Preparedness and Response, the Biomedical Advanced Research and Development Authority, and the Food and Drug Administration; and
 (B)the Department of Defense; and (4)biodefense stakeholders, as applicable.
 (c)Initial assessmentNot later than 7 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives an initial assessment of the effectiveness of the priority review voucher program set forth in section 565A of the Federal Food, Drug, and Cosmetic Act (as added by section 7).
 (d)ReportNot later than 12 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report containing the results of the study conducted under subsection (a).
 (e)Protection of national securityThe Comptroller General of the United States shall conduct the study and issue the assessment and report under this section in a manner that does not compromise national security.March 14, 2016Reported with an amendment


IV
112th CONGRESS
1st Session
H. RES. 6
In the House of Representatives, U. S.,

January 5, 2011

RESOLUTION

That the following named Members be, and are hereby, elected to the following standing committees of the House of Representatives:

Committee on Agriculture:Mr. Lucas, Chairman.

Committee on Appropriations:Mr. Rogers of Kentucky, Chairman; Mr. Young of Florida; Mr. Lewis of California; Mr. Wolf; Mr. Kingston; Mr. Frelinghuysen; Mr. Latham; Mr. Aderholt; Mrs. Emerson; Ms. Granger; Mr. Simpson; Mr. Culberson; Mr. Crenshaw; Mr. Rehberg; Mr. Carter; Mr. Alexander; Mr. Calvert; Mr. Bonner; Mr. LaTourette; Mr. Cole; Mr. Flake; Mr. Diaz-Balart; Mr. Dent; Mr. Austria; Mrs. Lummis; Mr. Graves of Georgia; Mr. Yoder; Mr. Womack; and Mr. Nunnelee.

Committee on Armed Services:Mr. McKeon, Chairman.

Committee on the Budget:Mr. Ryan of Wisconsin, Chairman.

Committee on Education and the Workforce:Mr. Kline, Chairman.

Committee on Energy and Commerce:Mr. Upton, Chairman.

Committee on Ethics:Mr. Bonner, Chairman; Mr. McCaul; Mr. Conaway; Mr. Dent; and Mr. Harper.

Committee on Financial Services:Mr. Bachus, Chairman.

Committee on Foreign Affairs:Ms. Ros-Lehtinen, Chairman.

Committee on Homeland Security:Mr. King of New York, Chairman.

Committee on House Administration:Mr. Daniel E. Lungren of California, Chairman; Mr. Harper; Mr. Gingrey of Georgia; Mr. Schock; Mr. Rokita; and Mr. Nugent.

Committee on the Judiciary:Mr. Smith of Texas, Chairman.

Committee on Natural Resources:Mr. Hastings of Washington, Chairman.

Committee on Oversight and Government Reform:Mr. Issa, Chairman.

Committee on Rules:Mr. Dreier, Chairman; Mr. Sessions; Ms. Foxx; Mr. Woodall; Mr. Nugent; Mr. Scott of South Carolina; and Mr. Webster.

Committee on Science, Space, and Technology:Mr. Hall, Chairman.

Committee on Small Business:Mr. Graves of Missouri, Chairman.

Committee on Transportation and Infrastructure:Mr. Mica, Chairman.

Committee on Veterans’ Affairs:Mr. Miller of Florida, Chairman.

Committee on Ways and Means:Mr. Camp, Chairman; Mr. Herger; Mr. Sam Johnson of Texas; Mr. Brady of Texas; Mr. Ryan of Wisconsin; Mr. Nunes; Mr. Tiberi; Mr. Davis of Kentucky; Mr. Reichert; Mr. Boustany; Mr. Heller; Mr. Roskam; Mr. Gerlach; Mr. Price of Georgia; Mr. Buchanan; Mr. Smith of Nebraska; Mr. Schock; Mr. Lee of New York; Ms. Jenkins; Mr. Paulsen; Mr. Berg; and Mrs. Black.

Lorraine C. Miller,Clerk.


113 HR 2775 IH: VA Quality Health Care Accountability and Transparency Act
U.S. House of Representatives
2021-04-22
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I117th CONGRESS1st SessionH. R. 2775IN THE HOUSE OF REPRESENTATIVESApril 22, 2021Mr. Gallego (for himself and Mr. Joyce of Ohio) introduced the following bill; which was referred to the Committee on Veterans' AffairsA BILLTo direct the Secretary of Veterans Affairs to make certain information publicly available on one internet website of the Department of Veterans Affairs.1.Short titleThis Act may be cited as the VA Quality Health Care Accountability and Transparency Act.2.Improved transparency by Department of Veterans Affairs(a)Publication of staffing and quality of care dataNot later than one year after the date of the enactment of this Act, the Secretary of Veterans Affairs shall make publicly available on the Access to Care internet website of the Department of Veterans Affairs (or a successor website) the information under subsection (b).(b)Information included(1)In generalThe information published on the internet website under subsection (a) shall include—(A)any numeric indicators relating to timely care, effective care, safety, and veteran-centered care that the Secretary collects at medical facilities of the Department pursuant to section 1703C of title 38, United States Code;(B)the staffing and vacancy information required by subparagraphs (A) through (D) of section 505(a)(1) of the VA MISSION Act of 2018 (Public Law 115–182; 38 U.S.C. 301 note);(C)the patient wait times information required by subsection (a) of section 206 of the Veterans Access, Choice, and Accountability Act of 2014 (Public Law 113–146; 128 Stat. 1780); and(D)the patient safety, quality of care, and outcome measures required by subsection (b) of such section.(2)UpdatesThe Secretary shall regularly update the internet website under subsection (a) to ensure that the information under paragraph (1) is the most current information required by the provisions of law specified in such paragraph.(c)Requirements of internet websiteIn addition to the requirements of section 206(b)(4) of the Veterans Access, Choice, and Accountability Act of 2014 (Public Law 113–146; 128 Stat. 1781), the Secretary shall ensure that the internet website under subsection (a) meets the following requirements:(1)The internet website is directly accessible from—(A)the main homepage of the publicly accessible internet website of the Department; and(B)the main homepage of the publicly accessible internet website of each medical center of the Department.(2)Where practicable, the internet website is organized and searchable by each medical center of the Department.(3)The internet website is easily understandable and usable by the general public.(d)Consultation and contract authorityIn carrying out subsection (c)(3), the Secretary—(1)shall consult with veterans service organizations; and(2)may enter into a contract to design the internet website under subsection (a) with a company, non-profit entity, or other entity, specializing in website design that has substantial experience in presenting health care data and information in a easily understandable and usable manner to patients and consumers.(e)Accuracy of data(1)Annual processNot later than 18 months after the date of the enactment of this Act, the Secretary shall develop and implement an annual process to audit a generalizable subset of the data contained in the internet website under subsection (a) to assess the accuracy and completeness of the data.(2)CriteriaThe Secretary shall ensure that each audit under subsection (a)—(A)determines the extent that the medical record information, clinical information, data, and documentation provided by each medical center of the Department that is used to calculate the information under subsection (b) is accurate and complete;(B)identifies any deficiencies in the recording of medical record information, clinical information, or data by medical centers of the Department that affects the accuracy and completeness of the information under subsection (b); and(C)provides recommendations to medical centers of the Department on how to—(i)improve the accuracy and completeness of the medical record information, clinical information, data, and documentation that is used to calculate the information under subsection (b); and(ii)ensure that each medical center of the Department provides such information in a uniform manner.(3)Annual reportsNot later than two years after the date of the enactment of this Act, and annually thereafter, the Secretary shall submit to Congress a report on the findings of each audit under paragraph (1).


116 SRES 524 IS: Condemning the practice of politically motivated imprisonment, calling for the immediate release of political prisoners in the Russian Federation, and urging action by the United States Government to impose sanctions with respect to persons responsible for that form of human rights abuse.
U.S. Senate
2020-03-02
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

III116th CONGRESS2d SessionS. RES. 524IN THE SENATE OF THE UNITED STATESMarch 2, 2020Mr. Cardin (for himself, Mr. Rubio, Mr. Coons, Mr. Johnson, and Mrs. Shaheen) submitted the following resolution; which was referred to the Committee on Foreign RelationsRESOLUTIONCondemning the practice of politically motivated imprisonment, calling for the immediate release of political prisoners in the Russian Federation, and urging action by the United States Government to impose sanctions with respect to persons responsible for that form of human rights abuse.Whereas the right to liberty and security of a person and the protection from arbitrary imprisonment are among the principal human rights guaranteed by Article 9 of the International Covenant on Civil and Political Rights, Article 23 of the Concluding Document of the Vienna Meeting of the Conference on Security and Cooperation in Europe, and Article 5 of the European Convention on Human Rights;Whereas the Russian Federation, as a member of the United Nations, the Organization for Security and Co-operation in Europe (OSCE), and the Council of Europe, is bound by international commitments with regard to human rights and the rule of law;Whereas, on October 3, 2012, the Parliamentary Assembly of the Council of Europe adopted Resolution 1900 (2012) that defined anyone whose detention has been imposed in violation of one of the fundamental guarantees set out in the European Convention on Human Rights and its Protocols or is the result of proceedings which were clearly unfair and this appears to be connected with political motives of the authorities as a political prisoner;Whereas, on July 2, 2014, the OSCE Parliamentary Assembly adopted the Baku Declaration in which it endorses the adoption by the Parliamentary Assembly of the Council of Europe of a resolution confirming the definition of political prisoners and strongly urges participating states to co-operate with international institutions like the OSCE, to help ensure that … there will be no political prisoners in the OSCE area;Whereas, based on the criteria of the Parliamentary Assembly of the Council of Europe Resolution 1900 (2012), the Memorial Human Rights Center, one of the most respected nongovernmental organizations in the Russian Federation, estimates that there are currently more than 300 political prisoners in the Russian Federation;Whereas the list of Russian political prisoners designated by the Memorial Human Rights Center includes journalists, civil society activists, human rights advocates, participants of peaceful demonstrations, adherents of prohibited religious groups, members of undesirable organizations, and Ukrainian citizens from the illegally annexed Crimea;Whereas the longest-serving political prisoner in the Russian Federation, Alexey Pichugin, has been incarcerated since June 19, 2003, in violation of 2 rulings by the European Court of Human Rights and the opinion by the United Nations Working Group on Arbitrary Detention;Whereas opposition activist Konstantin Kotov was sentenced to 4 years’ imprisonment on September 5, 2019, for participating in peaceful demonstrations, in a ruling Human Rights Watch has described as an outrageous violation of the right to peaceful protest;Whereas Anastasia Shevchenko, an activist in the Open Russia movement, has been held under house arrest since January 23, 2019, on the charge of belonging to an undesirable organization and has been designated by Amnesty International as a prisoner of conscience;Whereas Yuri Dmitriev, a historian and the leader of the Memorial Human Rights Center’s branch in the Republic of Karelia who has worked to document mass burial sites from Stalin-era executions, is being held in pretrial detention on charges of child pornography that Human Rights Watch has described as bogus and part of an ongoing smear campaign;Whereas Dennis Christensen, a Jehovah’s Witness and a citizen of Denmark, was sentenced to 6 years’ imprisonment on February 6, 2019, in a decision condemned by the United States Commission on International Religious Freedom as part of the broader pattern of the Government of the Russian Federation engaging in or tolerating severe violations of religious freedom;Whereas, on February 10, 2020, a court in Penza sentenced 7 activists to prison terms ranging from 6 to 18 years for participation in what authorities alleged was a terrorist organization called Network after a trial marked by incommunicado detention, torture, and other ill treatment to extract confessions, in what Human Rights Watch has described as an example of the Russian authorities abusing counterterrorism laws to silence critics and deny fundamental human rights;Whereas, on June 18, 2018, the Department of State affirmed that the United States is deeply concerned by the growing number of individuals … identified by credible human rights organizations as political and religious prisoners held by the Government of the Russian Federation and called on the Government of the Russian Federation to release all those identified as political or religious prisoners immediately and cease its use of the legal system to suppress dissent and peaceful religious practice;Whereas, on January 28, 2020, 43 parliamentarians from 16 European countries introduced a resolution in the Parliamentary Assembly of the Council of Europe calling for the appointment of a rapporteur to examine the growing crisis with politically motivated imprisonments in the Russian Federation; andWhereas, according to the Memorial Human Rights Center, the number of political prisoners in the Russian Federation has increased more than 6-fold since 2015: Now, therefore, be it That the Senate—(1)expresses support for those unjustly imprisoned in the Russian Federation;(2)condemns the practice of politically motivated imprisonment in the Russian Federation, which violates the commitments of the Russian Federation to international obligations with respect to human rights and the rule of law;(3)calls on the Government of the Russian Federation to immediately release political prisoners, including Alexey Pichugin, Konstantin Kotov, Anastasia Shevchenko, Yuri Dmitriev, and Dennis Christensen;(4)urges the United States Government, in all its interactions with the Government of the Russian Federation, to raise individual cases of political prisoners held by the Russian Federation and to press for their release; and(5)urges the Secretary of State and the Secretary of the Treasury to use their authority under the Sergei Magnitsky Rule of Law Accountability Act of 2012 (title IV of Public Law 112–208; 22 U.S.C. 5811 note), the Global Magnitsky Human Rights Accountability Act (subtitle F of title XII of Public Law 114–328; 22 U.S.C. 2656 note), and other applicable provisions of law to designate for the imposition of sanctions officials of the Government of the Russian Federation who are responsible for human rights abuses in the form of politically motivated imprisonment.


		I
		111th CONGRESS
		1st Session
		H. R. 1273
		IN THE HOUSE OF REPRESENTATIVES

			March 3, 2009
			Mrs. Maloney (for
			 herself and Mr. Arcuri) introduced the
			 following bill; which was referred to the Committee on Oversight and Government
			 Reform

		A BILL
		To honor Susan B. Anthony by celebrating her legacy on
		  the third Monday in February.

		1.Short TitleThis Act may be cited as the Susan B.
			 Anthony Birthday Act.
		2.FindingsCongress finds the following:
			(1)Susan Brownell
			 Anthony created the first women’s movement in the United States and led that
			 movement for more than 50 years.
			(2)Born in South
			 Adams, Massachusetts, on February 15, 1820, Susan B. Anthony met Elizabeth Cady
			 Stanton in 1851 and attended her first women’s rights convention in Syracuse in
			 1852, where she joined the fight to get women the right to vote, arguing that
			 the right women needed above every other . . . was the right of
			 suffrage.
			(3)The first proposal
			 for women’s suffrage was presented to Congress in 1868.
			(4)Susan B. Anthony
			 appeared before every Congress from 1869 to 1906 to ask for passage of a
			 suffrage amendment.
			(5)Susan B. Anthony
			 served as the president of the National Woman Suffrage Association from 1892
			 until 1900.
			(6)Designated then as
			 the 16th amendment, the first formal women’s suffrage amendment to the
			 Constitution of the United States was introduced in January 1878 and stated,
			 The right of citizens to vote shall not be abridged by the United States
			 or by any State on account of sex.. This same amendment was introduced
			 in every session of Congress for the next 41 years.
			(7)Before her death on
			 March 13, 1906, Susan B. Anthony’s last public words were Failure is
			 impossible..
			(8)On May 21, 1919,
			 the House of Representatives passed the 19th amendment, and 2 weeks later, the
			 Senate followed.
			(9)On August 18,
			 1920, when Tennessee became the 36th State to ratify the amendment, the
			 amendment passed its final hurdle of obtaining the agreement of three-fourths
			 of the states. Secretary of State Bainbridge Colby certified the ratification
			 on August 26, 1920.
			(10)The text of the
			 19th amendment is: The right of citizens of the United States to vote
			 shall not be denied or abridged by the United States or by any State on account
			 of sex. Congress shall have power to enforce this article by appropriate
			 legislation..
			(11)In 1921, a marble
			 statue of Susan B. Anthony and her women’s rights colleagues, Lucretia Mott and
			 Elizabeth Cady Stanton, was dedicated in the United States Capitol.
			(12)Susan B.
			 Anthony’s picture has appeared on two postage stamps, the 3-cent purple stamp
			 issued in 1936 and the 50-cent deeper purple stamp issued in 1955.
			(13)Susan B. Anthony’s
			 home in Rochester, New York, has been a National Historic Landmark since
			 1966.
			(14)In 1979, Susan B.
			 Anthony was honored by having her image placed on a dollar coin.
			(15)No Federal holiday
			 celebrates the birthday of a woman.
			3.Celebrating Susan
			 B. Anthony’s legacy on the third Monday in FebruarySection 6103(a) of title 5, United States
			 Code, is amended by striking the third Monday in February and
			 inserting the third Monday in February, on which day the Nation shall
			 also celebrate the legacy of Susan B. Anthony.


115 HR 442 IH: Cuba Trade Act of 2017
U.S. House of Representatives
2017-01-11
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS1st SessionH. R. 442IN THE HOUSE OF REPRESENTATIVESJanuary 11, 2017Mr. Emmer (for himself, Ms. Castor of Florida, Mr. Beyer, Mr. Sanford, Ms. Lee, Mr. Pocan, Mr. Amash, Mr. Crawford, Mr. McGovern, and Mr. Poe of Texas) introduced the following bill; which was referred to the Committee on Foreign Affairs, and in addition to the Committees on Ways and Means, Financial Services, and Agriculture, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concernedA BILLTo lift the trade embargo on Cuba, and for other purposes.

 1.Short titleThis Act may be cited as the Cuba Trade Act of 2017. 2.Removal of provisions restricting trade with Cuba (a)Authority for Embargo (1)In generalSection 620(a) of the Foreign Assistance Act of 1961 (22 U.S.C. 2370(a)) is amended by striking (1) No assistance and all that follows through (2) Except and inserting Except.
 (2)Conforming amendmentSection 1709 of the Cuban Democracy Act of 1992 (22 U.S.C. 6008) is amended by striking section 620(a)(2) and inserting section 620(a). (b)Cuban Democracy Act (1)In generalThe Cuban Democracy Act of 1992 (22 U.S.C. 6001 et seq.) is amended—
 (A)by striking section 1704 (22 U.S.C. 6003); (B)by striking section 1706 (22 U.S.C. 6005); and
 (C)by striking section 1708 (22 U.S.C. 6007). (2)Conforming amendmentParagraph (3) of section 204(b) of the Cuban Liberty and Democratic Solidarity (LIBERTAD) Act of 1996 (22 U.S.C. 6064(b)) is amended to read as follows:

 (3)section 1705(d) of the Cuban Democracy Act of 1992 (22 U.S.C. 6004(d));. (c)Cuban Liberty and Democratic Solidarity ActThe Cuban Liberty and Democratic Solidarity (LIBERTAD) Act of 1996 (22 U.S.C. 6021 et seq.) is amended—
 (1)by striking section 102 (22 U.S.C. 6032); (2)by striking section 103 (22 U.S.C. 6033); and
 (3)in section 109(a) (22 U.S.C. 6039(a)), by striking (including section 102 of this Act). (d)Trade Sanctions Reform and Export Enhancement Act of 2000The Trade Sanctions Reform and Export Enhancement Act of 2000 (22 U.S.C. 7201 et seq.) is amended—
 (1)in section 906(a)(1) (22 U.S.C. 7205(a)(1)), by striking Cuba,; (2)by amending section 908 (22 U.S.C. 7207) to read as follows:

						908.Prohibition on United States assistance and financing
 (a)In generalNotwithstanding any other provision of law, no United States Government assistance, including United States foreign assistance, United States export assistance, and any United States credit or guarantees shall be available for commercial exports to Iran, Libya, North Korea, or Sudan.
 (b)Prohibition on foreign assistance and financing of trade with CubaNotwithstanding any other provision of law, the United States Government may not provide any foreign assistance to Cuba or any financial assistance, loans, loan guarantees, extension of credit, or other financing for exports to Cuba.
 (c)WaiverThe President may waive the application of subsection (a) or (b) to the degree the President determines that it is in the national security interest of the United States to do so, or for humanitarian reasons.; and
 (3)by striking section 909 (22 U.S.C. 7208). 3.Prohibition on use of taxpayer funds to promote trade with Cuba (a)In generalNotwithstanding any other provision of law, the Federal Government may not obligate or expend any funds to promote trade with or develop markets in Cuba.
 (b)Exclusion of certain Federal commodity promotion programsSubsection (a) does not prohibit the obligation or expenditure of funds by Federal commodity promotion programs established in accordance with a commodity promotion law, as defined by section 501(a) of the Federal Agriculture Improvement and Reform Act of 1996 (7 U.S.C. 7401(a)).


115 HR 6864 IH: To require the Federal Trade Commission to promulgate regulations related to sensitive personal information or behavioral data, and for other purposes.
U.S. House of Representatives
2018-09-24
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I115th CONGRESS2d SessionH. R. 6864IN THE HOUSE OF REPRESENTATIVESSeptember 24, 2018Ms. DelBene (for herself and Mr. Jeffries) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo require the Federal Trade Commission to promulgate regulations related to sensitive personal
			 information or behavioral data, and for other purposes.

 1.Short titleThis Act may be cited as the Information Transparency & Personal Data Control Act. 2.Requirements for sensitive personal information or behavioral data (a)RegulationsNot later than 1 year after the date of the enactment of this Act, the Federal Trade Commission shall promulgate regulations under section 553 of title 5, United States Code, to require, except as provided in subsection (b), any operator that provides services to the public involving the collection, storage, processing, sale, sharing with third parties, or other use of sensitive personal information from United States persons or persons located in the United States when the data is collected, to meet the following requirements:
 (1)Affirmative, express, and opt in consentProvide users with notice through a privacy and data use policy of a specific request to use their data and require that users provide affirmative, express, and opt in consent to any functionality that involves the collection, storage, processing, sale, sharing, or other use of sensitive personal information, including sharing personal data with third parties.
 (2)Privacy and data use policyProvide users with an up-to-date, transparent privacy, security, and data use policy that meets general requirements, including that such policy, presented to users in the context where it applies—
 (A)is concise and intelligible; (B)is clear and prominent in appearance;
 (C)uses clear and plain language; (D)uses visualizations where appropriate to make complex information understandable by the ordinary user; and
 (E)is provided free of charge. (3)Additional requirements for privacy and data use policyThe privacy, security, and data use policy required under paragraph (2) shall include the following:
 (A)Identity and contact information of the entity collecting the sensitive personal information. (B)The purpose or use for collecting, storing, processing, selling, sharing, or otherwise using the personal information, including how the sensitive personal information is shared with third parties.
 (C)Third parties with whom the sensitive personal information will be shared and for what purposes. (D)The storage period for how long the personal information will be retained by the operator and any third party, as applicable.
 (E)How consent to collecting, storing, processing, selling, sharing, or otherwise using the sensitive personal information, including sharing with third parties, may be withdrawn.
 (F)How a user can view the sensitive personal information that they have provided to an operator and whether it can be exported to other web-based platforms.
 (G)What kind of sensitive personal information is collected. (H)Whether the sensitive personal information will be used to create profiles about users.
 (I)How sensitive personal information is protected from unauthorized access or acquisition. (4)Opt out consentFor any collection, storage, processing, selling, sharing, or other use of non-sensitive personal information, including sharing with third parties, Operators shall provide users with the ability to opt out at any time.
				(5)Privacy audits
 (A)In generalAnnually, Operators collecting, storing, processing, selling, sharing, or otherwise using sensitive personal information shall obtain a privacy audit from an objective, independent third-party professional with substantial experience in the field of privacy and data protection, who uses procedures and standards generally accepted in such field.
 (B)Audit requirementsEach such audit shall— (i)set forth the privacy, security, and data use controls that the operator has implemented and maintained during the reporting period;
 (ii)describe whether such controls are appropriate to the size and complexity of the operator, the nature and scope of the activities of the operator, and the nature of the sensitive personal information or behavioral data collected by the operator;
 (iii)certify whether the privacy and security controls operate with sufficient effectiveness to provide reasonable assurance to protect the privacy and security of sensitive personal information or behavioral data and that the controls have so operated throughout the reporting period;
 (iv)be prepared and completed within 60 days after the end of the reporting period to which the audit applies; and
 (v)be provided to the Federal Trade Commission or to the attorney general of a State, or other authorized State officer, within 10 days of notification by the Commission or the attorney general of a State, or other authorized State officer where such person has presented to the Operator allegations that a violation of this Act or any regulation issued under this Act has been committed by the Operator.
 (C)Small business exemptionNotwithstanding other authorities of the FTC, the audit requirements set forth above shall not apply to Operators with 500 or fewer employees.
 (D)Non-sensitive personal information exemptionThe audit requirements set forth above shall not apply to Operators who do not collect, store, process, sell, share, or otherwise use sensitive personal information.
					(b)Exemptions
 (1)Necessary operations and security purposesSubsection (a) shall not apply to the processing, collecting, storing, sharing, selling of sensitive personal information for the following purposes:
 (A)Preventing or detecting fraud. (B)Protecting the security of people, devices, networks, or facilities.
 (C)Protecting the health, safety, rights, or property of the covered entity or another person. (D)Responding in good faith to valid legal process or providing information as otherwise required or authorized by law.
 (E)Monitoring or enforcing agreements between the covered entity and an individual, including but not limited to, terms of service, terms of use, user agreements, or agreements concerning monitoring criminal activity.
 (2)Reasonable expectation of usersThe regulations promulgated pursuant to subsection (a) with respect to the requirement to provide opt in consent shall not apply to the processing of sensitive personal information or behavioral data in which such processing does not deviate from purposes consistent with an operator’s relationship with users as understood by the reasonable user.
				3.Application and enforcement by the Federal Trade Commission
 (a)General applicationThis Act applies, according to its terms, to those persons, partnerships, and corporations over which the Federal Trade Commission has authority pursuant to section 5(a)(2) of the Federal Trade Commission Act (15 U.S.C. 45(a)(2)). Notwithstanding the limitations in the Federal Trade Commission Act on Commission authority with respect to common carriers, this Act also applies, according to its terms, to common carriers subject to the Communications Act of 1934 (47 U.S.C. 151 et seq.) and Acts amendatory thereof and supplementary thereto.
			(b)Enforcement
 (1)Unfair or deceptive acts or practicesA violation of this Act or a regulation promulgated under this Act shall be treated as a violation of a regulation under section 18(a)(1)(B) of the Federal Trade Commission Act (15 U.S.C. 57a(a)(1)(B)) regarding unfair or deceptive acts or practices.
 (2)Powers of CommissionExcept as provided in subsection (a), the Federal Trade Commission shall enforce this Act and the regulations promulgated under this Act in the same manner, by the same means, and with the same jurisdiction, powers, and duties as though all applicable terms and provisions of the Federal Trade Commission Act (15 U.S.C. 41 et seq.) were incorporated into and made a part of this Act. Any person who violates this Act or a regulation promulgated under this Act shall be subject to the penalties and entitled to the privileges and immunities provided in the Federal Trade Commission Act.
 (c)ConstructionNothing in this Act shall be construed to limit the authority of the Federal Trade Commission under any other provision of law.
 4.DefinitionsIn this Act: (1)Call detail recordThe term call detail record—
 (A)means session-identifying information (including an originating or terminating telephone number, an International Mobile Subscriber Identity number, or an International Mobile Station Equipment Identity number), a telephone calling card number, or the time or duration of a call;
 (B)does not include— (i)the contents (as defined in section 2510(8) of title 18, United States Code) of any communication;
 (ii)the name, address, or financial information of a subscriber or customer; or (iii)cell site location or global positioning system information.
 (2)Clear and prominentThe term clear and prominent means in any communication medium, the required disclosure is— (A)of a type, size, and location sufficiently noticeable for an ordinary consumer to read and comprehend the communication;
 (B)provided in a manner such that an ordinary consumer is able to read and comprehend the communication;
 (C)is presented in an understandable language and syntax; (D)includes nothing contrary to, inconsistent with, or that mitigates any statement contained within the disclosure or within any document linked to or referenced therein; and
 (E)includes an option that is compliant with applicable obligations of the operator under title III of the Americans with Disabilities Act of 1990 (42 U.S.C. 12181 et seq.).
 (3)CommissionThe term Commission means the Federal Trade Commission. (4)OperatorThe term operator means any entity who operates a website located on the internet or an online service and who collects or maintains personal information from or about individuals, or on whose behalf such information is collected or maintained, where such website or online service is operated for commercial purposes, including any entity that buys and sells consumer data without direct consumer interaction, and any entity offering products or services for sale through that website or online service, involving commerce among the States or with one or more foreign nations.
 (5)Sensitive personal informationThe term sensitive personal information means information relating to an identified or identifiable individual, including the following: (A)Financial information.
 (B)Health information. (C)Relationships.
 (D)Information pertaining to children under 13 years of age. (E)Social Security numbers.
 (F)Driver’s license or other government-issued identification number. (G)Authentication credentials, such as a username and password.
 (H)Precise geolocation information. (I)Content of communications.
 (J)Call detail records. (K)Web browsing history, application usage history, and the functional equivalent of either.
 (L)Biometric information. (M)Sexual orientation.
 (N)Political preferences. (O)Religious beliefs.
 (P)Any other personal or behavioral information that the Commission determines to be sensitive. (6)StateThe term State means each State of the United States, the District of Columbia, and each commonwealth, territory, or possession of the United States.
 (7)Third partyThe term third party means an individual or entity that uses or receives sensitive personal information or behavioral data obtained by or on behalf of an operator, other than—
 (A)a service provider of an operator to whom the operator discloses the consumer’s sensitive personal information for an operational purpose pursuant to an agreement that prohibits the person receiving the personal information from using or disclosing the personal information for any purpose other than the purposes contemplated by the agreement; and
 (B)any entity that uses such data only as reasonably necessary— (i)to comply with applicable law, regulation, or legal process;
 (ii)to enforce an operator’s terms of use; or (iii)to detect, prevent, or mitigate fraud or security vulnerabilities.
 5.Rule of constructionNothing in this Act shall be construed to preclude the acquisition by the Federal Government of— (1)the contents of a wire or electronic communication pursuant to other lawful authorities, including the authorities under chapter 119 of title 18, United States Code (commonly known as the Wiretap Act), the Foreign Intelligence Surveillance Act of 1978 (50 U.S.C. 1801 et seq.), or any other provision of Federal law not specifically amended by this Act; or
 (2)records or other information relating to a subscriber or customer of any electronic communication service or remote computing service (not including the content of such communications) pursuant to the Foreign Intelligence Surveillance Act of 1978 (50 U.S.C. 1801 et seq.), chapter 119 of title 18, United States Code (commonly known as the Wiretap Act), or any other provision of Federal law not specifically amended by this Act.
			6.Right of action
 (a)Right of actionExcept as provided in subsection (e), the attorney general of a State, or other authorized State officer, alleging a violation of this Act or any regulation issued under this Act that affects or may affect such State or its residents may bring an action on behalf of the residents of the State in any United States district court for the district in which the defendant is found, resides, or transacts business, or wherever venue is proper under section 1391 of title 28, to obtain appropriate injunctive relief.
 (b)Notice to commission requiredA State shall provide prior written notice to the Federal Trade Commission of any civil action under subsection (a) together with a copy of its complaint, except that if it is not feasible for the State to provide such prior notice, the State shall provide such notice immediately upon instituting such action.
 (c)Intervention by the CommissionThe Commission may intervene in such civil action and upon intervening— (1)be heard on all matters arising in such civil action; and
 (2)file petitions for appeal of a decision in such civil action. (d)ConstructionNothing in this section shall be construed—
 (1)to prevent the attorney general of a State, or other authorized State officer, from exercising the powers conferred on the attorney general, or other authorized State officer, by the laws of such State; or
 (2)to prohibit the attorney general of a State, or other authorized State officer, from proceeding in State or Federal court on the basis of an alleged violation of any civil or criminal statute of that State.
 (e)LimitationNo separate suit shall be brought under this section if, at the time the suit is brought, the same alleged violation is the subject of a pending action by the Federal Trade Commission or the United States under this chapter.
 7.Effective dateThis Act shall take effect 180 days after the date of the enactment of this Act.


117 HR 5256 IH: Flood History Information Act of 2021
U.S. House of Representatives
2021-09-14
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I117th CONGRESS1st SessionH. R. 5256IN THE HOUSE OF REPRESENTATIVESSeptember 14, 2021Mrs. Luria (for herself, Mr. Garbarino, and Ms. Dean) introduced the following bill; which was referred to the Committee on Financial ServicesA BILLTo provide for the disclosure and sharing of certain policy and claims information under the National Flood Insurance Program, and for other purposes.1.Short titleThis Act may be cited as the Flood History Information Act of 2021.2.Data exchange programSection 1313 of the National Flood Insurance Act of 1968 (42 U.S.C. 4020) is amended—(1)by inserting after the section enumerator the following: (a) Availability of flood insurance information.—; and(2)by adding at the end the following new subsections:(b)Data exchange program(1)In generalThe Administrator shall disclose policy and claims information described in paragraph (2) to an insurance company, as such term is defined in subsection (f), if such insurance company has entered into a data sharing agreement with the Administrator pursuant to paragraph (3).(2)Data eligible for sharingThe Administrator shall disclose the following claims and policy information, obtained in connection with a flood insurance policy made available under this title or through a data sharing agreement executed pursuant to paragraph (3), pursuant to paragraph (1):(A)The location of the insured property, by address and latitude and longitude).(B)Amount of coverage in force.(C)Dates of loss.(D)The amount paid on claims.(E)Any other claims and policy information the Administrator determines necessary and appropriate.(3)Data sharing agreementA data sharing agreement entered into pursuant to paragraph (1) shall include—(A) the terms and conditions under which insurance companies may use, share, store, and account for the data, which shall at minimum include provisions ensuring that—(i)the insurance company may only use information provided under the agreement for the purposes of underwriting, establishing premium rates, and adjusting claims; and(ii)the insurance company may not use the information provided as part of the agreement for marketing purposes;(B)an agreement by the insurance company to provide to the Administrator the insurance company’s policy and claims data in a form prescribed by the Administrator; and(C)any other terms and conditions the Administrator determines are necessary and appropriate.(c)Access to flood insurance informationUpon the request of a purchaser, lessee, or current owner of a property, the Administrator shall provide to the purchaser, lessee, or current owner of the property information pertaining to the property the purchaser or lessee is under contract to buy or lease, respectively, or the current owner’s property, as follows:(1)The number and dollar value of claims filed for the property, and factors related to the cause of loss, over the life of the property, as known to the Administrator, including claims made under—(A)a flood insurance policy made available under this Act; and(B)a private flood insurance policy.(2)Information on whether the property owner may be required to purchase flood insurance coverage due to previous receipt of Federal disaster assistance subject to the mandatory purchase requirement under section 102 of the Flood Disaster Protection Act of 1973.(3)Such other available information about the property as determined by the Administrator to accurately and adequately characterize the true flood risk to the property.(d)Privacy protectionDisclosure of information contained within a system of records (as such term is defined in section 552a(a)(5) of title 5, United States Code) as authorized in subsections (b) and (c) of this section shall be considered a routine use for the purposes of section 552a(3) of title 5, United States Code.(e)Fee(1)In generalTo carry out subsection (b), the Administrator may charge a fee to participating insurance companies under subsection (b). The Administrator shall not charge a fee to the current owner requesting flood insurance information under subsection (c).(2)DepositThe Administrator shall deposit the fee collected under this subsection into the National Flood Insurance Fund established under section 1310.(f)DefinitionFor the purposes of this section the following definitions shall apply:(1)Insurance companyThe term insurance company means an insurance company that meets the requirements of subparagraph (A) of section 102(b)(7) of the Flood Disaster Protection Act of 1973 (42 U.S.C. 4012a(b)(7)(A).(2)LesseeThe term lessee means a person who enters into an agreement to lease, rent, or sublease a property.(3)PurchaserThe term purchaser means a person or entity that enters into an agreement to purchase an interest in a property..


116 HR 5997 IH: Emergency Response Coordinator Act of 2020
U.S. House of Representatives
2020-02-27
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I116th CONGRESS2d SessionH. R. 5997IN THE HOUSE OF REPRESENTATIVESFebruary 27, 2020Mr. Engel introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo direct the Secretary of Health and Human Services to designate an official within the Department of Health and Human Services to coordinate the efforts of Federal departments and agencies with respect to COVID–19.1.Short titleThis Act may be cited as the Emergency Response Coordinator Act of 2020.2.COVID–19 Response CoordinatorThe Secretary of Health and Human Services shall designate an official within the Department of Health and Human Services to coordinate the efforts of Federal departments and agencies with respect to COVID–19.